The Cardinal Weekly |
Eli Lilly's stock surges toward record after positive trials for diabetes treatments
MarketWatch Shares of Eli Lilly & Co. LLY, +1.80% rallied 3.1% toward a record high in premarket trade Thursday, after drugmaker announced positive results from a trial of its diabetes treatment. The company said a phase 2b trial of dual GIP and GLP-1 receptor … Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in …BioSpace (press release) (blog) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a …The Lancet SEC FORM 4 – SEC.govSEC.gov all 150 news articles » |
More details can be found at www.diabeteshowto.com
Discussion
Comments are disallowed for this post.
Comments are closed.